Tumors Responding to DLL4 and VEGF Blockade
Dual blockade therapies targeting DLL4 and VEGF pathways represent a pioneering strategy in cancer treatment. By simultaneously inhibiting these key angiogenesis signals, these therapies offer promising results, particularly in resistant tumors. Clinical studies and innovative techniques, like bispecific antibodies and nanotechnology, highlight their potential to enhance traditional therapies and open new avenues in cancer management. […]
3 minute read